We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Antidote Technologies, a clinical trial matching platform, has raised £11m in a funding round led by Merck Global Health Innovation Fund (GHI) and joined by existing investors Smedvig Capital and Octopus Ventures.